IOVA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.40%

Insider Buying (Last 12 Months): $2,287,500.00

Insider Selling (Last 12 Months): $0.00

Iovance Biotherapeutics Insider Trading History Chart

Iovance Biotherapeutics Share Price & Price History

^$9.74

▲ +0.27 (2.85%)

As of 10/11/2024 01:00 AM ET

Days: 30 | 90 | 365

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Iovance Biotherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2024	Merrill A Mcpeak	Director	Buy	250,000	$9.15	$2,287,500.00	320,150
9/18/2023	Merrill A Mcpeak	Director	Buy	10,000	$5.56	$55,600.00	248,633
9/15/2023	Wayne P Rothbaum	Director	Buy	5,000,000	$5.30	$26,500,000.00	23,067,333
12/21/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.15	$61,500.00	70,150
12/2/2022	Wayne P Rothbaum	Director	Buy	10,000,000	$6.50	$65,000,000.00	18,067,333
11/28/2022	Frederick G Vogt	CEO	Buy	1,000	$5.98	$5,980.00	2,000
11/28/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.18	$61,800.00	228,633
11/23/2022	Iain D Dukes	Director	Buy	10,000	$6.10	$61,000.00	22,000
6/1/2022	Frederick G Vogt	CEO	Buy	1,000	$6.44	$6,440.00	1,000
5/31/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.84	$68,400.00	20,150

What Is the $7,882 Stimulus Payment 2024?

From Angel Publishing | Ad

Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.

Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here.

SEC Filings (Institutional Ownership Changes) for Iovance Biotherapeutics (NASDAQ:IOVA)

77.03% of Iovance Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Iovance Biotherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/11/2024	Creative Planning	73,489	$0.69M	0.0%	+2.6%	0.026%
10/11/2024	ORG Wealth Partners LLC	9,432	$89K	0.0%	N/A	0.003%
10/10/2024	Shaker Investments LLC OH	100,712	$0.95M	0.4%	+27.7%	0.036%
10/10/2024	Exchange Traded Concepts LLC	17,071	$0.16M	0.0%	+11.6%	0.006%
10/8/2024	Brookstone Capital Management	20,055	$0.19M	0.0%	+43.9%	0.007%
10/5/2024	Handelsbanken Fonder AB	74,800	$0.70M	0.0%	+18.2%	0.027%
8/19/2024	B. Riley Wealth Advisors Inc.	13,296	$0.11M	0.0%	N/A	0.005%
8/16/2024	Perceptive Advisors LLC	25,933,142	$207.98M	4.9%	+34.6%	9.267%
8/16/2024	Creative Planning	71,593	$0.57M	0.0%	-7.1%	0.026%
8/16/2024	Algert Global LLC	35,286	$0.28M	0.0%	-9.0%	0.013%
8/16/2024	Cim Investment Management Inc.	31,172	$0.25M	0.1%	+126.3%	0.011%
8/15/2024	Long Focus Capital Management LLC	4,132,000	$33.14M	1.3%	+195.1%	1.477%
8/15/2024	The Manufacturers Life Insurance Company	335,513	$2.69M	0.0%	-6.5%	0.120%
8/15/2024	Dark Forest Capital Management LP	44,858	$0.36M	0.1%	N/A	0.016%
8/15/2024	AQR Capital Management LLC	11,477	$92K	0.0%	-71.3%	0.004%
8/14/2024	Squarepoint Ops LLC	257,543	$2.07M	0.0%	N/A	0.092%
8/14/2024	Marshall Wace LLP	1,612,055	$12.93M	0.0%	N/A	0.576%
8/14/2024	Xponance Inc.	16,279	$0.13M	0.0%	+13.0%	0.006%
8/14/2024	Magnetar Financial LLC	82,363	$0.66M	0.0%	N/A	0.029%
8/14/2024	Hood River Capital Management LLC	2,732,427	$21.91M	0.5%	+4.1%	0.976%
8/14/2024	EverSource Wealth Advisors LLC	6,609	$58K	0.0%	N/A	0.002%
8/14/2024	ProShare Advisors LLC	49,061	$0.39M	0.0%	-21.1%	0.018%
8/14/2024	Profund Advisors LLC	124,660	$1M	0.0%	+33.1%	0.045%
8/13/2024	Ensign Peak Advisors Inc	74,592	$0.60M	0.0%	+13.4%	0.027%
8/13/2024	Sei Investments Co.	284,761	$2.28M	0.0%	-14.5%	0.102%
8/12/2024	Seven Eight Capital LP	77,240	$0.62M	0.1%	-55.7%	0.028%
8/12/2024	Vanguard Personalized Indexing Management LLC	22,085	$0.18M	0.0%	+27.2%	0.008%
8/12/2024	E Fund Management Co. Ltd.	40,912	$0.33M	0.0%	+48.2%	0.015%
8/10/2024	Virtu Financial LLC	94,099	$0.76M	0.1%	N/A	0.034%
8/9/2024	Edgestream Partners L.P.	99,605	$0.80M	0.0%	N/A	0.036%
8/9/2024	Pekin Hardy Strauss Inc.	35,050	$0.28M	0.0%	-18.6%	0.013%
8/9/2024	Dimensional Fund Advisors LP	2,265,555	$18.17M	0.0%	-21.1%	0.810%
8/8/2024	Wealthspire Advisors LLC	57,000	$0.46M	0.0%	N/A	0.020%
8/8/2024	Parametrica Management Ltd	261,090	$2.09M	2.8%	+98.4%	0.093%
8/8/2024	American Century Companies Inc.	203,038	$1.63M	0.0%	-40.0%	0.073%
8/8/2024	Rice Hall James & Associates LLC	1,636,025	$13.12M	0.8%	-4.5%	0.585%
8/7/2024	Headlands Technologies LLC	16,067	$0.13M	0.0%	N/A	0.006%
8/7/2024	Daiwa Securities Group Inc.	8,813	$71K	0.0%	+754.0%	0.003%
8/7/2024	Choreo LLC	14,354	$0.12M	0.0%	N/A	0.005%
8/6/2024	Quest Partners LLC	5,003	$40K	0.0%	+1,237.7%	0.002%
8/6/2024	Pier 88 Investment Partners LLC	58,580	$0.47M	0.1%	+155.8%	0.021%
8/6/2024	Los Angeles Capital Management LLC	24,124	$0.19M	0.0%	N/A	0.009%
8/6/2024	Candriam S.C.A.	500,033	$4.01M	0.0%	-52.8%	0.179%
8/5/2024	Arizona State Retirement System	54,734	$0.44M	0.0%	+3.8%	0.020%
8/3/2024	TD Asset Management Inc	284,878	$2.29M	0.0%	-43.6%	0.102%
8/1/2024	Rhumbline Advisers	368,800	$2.96M	0.0%	-5.8%	0.132%
7/31/2024	Abacus Planning Group Inc.	10,284	$82K	0.0%	N/A	0.004%
7/29/2024	Principal Financial Group Inc.	2,536,243	$20.34M	0.0%	+26.4%	0.906%
7/29/2024	Panagora Asset Management Inc.	361,187	$2.90M	0.0%	+11.6%	0.129%
7/26/2024	Bank of New York Mellon Corp	1,034,760	$8.30M	0.0%	+24.0%	0.370%
7/25/2024	Bank Pictet & Cie Europe AG	42,973	$0.35M	0.0%	-20.3%	0.015%
7/25/2024	Banque Pictet & Cie SA	668,650	$5.36M	0.0%	-3.0%	0.239%
7/22/2024	SeaCrest Wealth Management LLC	21,683	$0.17M	0.0%	N/A	0.008%
7/20/2024	Neo Ivy Capital Management	212,648	$1.71M	0.3%	N/A	0.076%
7/20/2024	Hennion & Walsh Asset Management Inc.	368,152	$2.95M	0.2%	-9.6%	0.132%
7/19/2024	Intellectus Partners LLC	113,929	$0.91M	0.2%	-3.4%	0.041%
7/18/2024	Brookstone Capital Management	13,935	$0.11M	0.0%	N/A	0.005%
7/17/2024	Clear Harbor Asset Management LLC	30,800	$0.25M	0.0%	N/A	0.011%
7/16/2024	ORG Partners LLC	3,974	$32K	0.0%	N/A	0.001%
7/16/2024	Diversified Trust Co	16,980	$0.14M	0.0%	+9.5%	0.006%
7/12/2024	SG Americas Securities LLC	498,390	$4M	0.0%	+836.5%	0.178%
7/5/2024	DNB Asset Management AS	28,022	$0.22M	0.0%	+65.5%	0.010%
7/2/2024	Transcend Capital Advisors LLC	22,500	$0.18M	0.0%	N/A	0.008%
5/24/2024	Farallon Capital Management LLC	26,000	$0.39M	0.0%	-95.4%	0.009%
5/17/2024	Zimmer Partners LP	43,500	$0.65M	0.0%	-91.2%	0.016%
5/16/2024	California State Teachers Retirement System	196,461	$2.91M	0.0%	-16.9%	0.070%
5/16/2024	Bayesian Capital Management LP	151,700	$2.25M	0.2%	+328.5%	0.054%
5/15/2024	Price T Rowe Associates Inc. MD	5,267,864	$78.07M	0.0%	+60.8%	1.883%
5/15/2024	Hood River Capital Management LLC	2,624,238	$38.89M	0.9%	+31.1%	0.938%
5/15/2024	Avoro Capital Advisors LLC	11,700,000	$173.39M	2.0%	+74.6%	4.181%
5/15/2024	Lazard Asset Management LLC	3,868	$56K	0.0%	-35.5%	0.001%
5/14/2024	CANADA LIFE ASSURANCE Co	43,878	$0.65M	0.0%	+89.9%	0.016%
5/14/2024	American International Group Inc.	116,951	$1.73M	0.0%	+2.6%	0.042%
5/13/2024	Seven Eight Capital LP	174,402	$2.59M	0.3%	N/A	0.062%
5/10/2024	Vanguard Group Inc.	24,915,300	$369.25M	0.0%	+9.2%	8.904%
5/9/2024	Mitsubishi UFJ Asset Management Co. Ltd.	42,805	$0.63M	0.0%	-4.4%	0.015%
5/9/2024	Roanoke Asset Management Corp NY	40,360	$0.60M	0.2%	-1.9%	0.014%
5/9/2024	State Board of Administration of Florida Retirement System	48,311	$0.72M	0.0%	-26.2%	0.017%
5/8/2024	ProShare Advisors LLC	62,210	$0.92M	0.0%	+14.5%	0.022%
5/8/2024	US Bancorp DE	31,557	$0.47M	0.0%	+113.8%	0.011%
5/7/2024	Sei Investments Co.	333,148	$4.94M	0.0%	+33.9%	0.119%
5/7/2024	Swiss National Bank	378,956	$5.62M	0.0%	-13.8%	0.135%
5/7/2024	Oppenheimer & Co. Inc.	16,625	$0.25M	0.0%	N/A	0.006%
5/7/2024	SG Americas Securities LLC	53,218	$0.79M	0.0%	-40.0%	0.019%
5/3/2024	GSA Capital Partners LLP	61,225	$0.91M	0.1%	N/A	0.022%
5/2/2024	Jennison Associates LLC	50,029	$0.74M	0.0%	-45.1%	0.018%
5/2/2024	Fidelis Capital Partners LLC	5,903	$87K	0.0%	N/A	0.002%
5/2/2024	Hussman Strategic Advisors Inc.	84,000	$1.25M	0.3%	N/A	0.030%
5/1/2024	BNP Paribas Financial Markets	145,924	$2.16M	0.0%	-73.6%	0.052%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	88,278	$1.31M	0.0%	-38.2%	0.032%
4/30/2024	J.W. Cole Advisors Inc.	10,577	$0.16M	0.0%	-83.0%	0.004%
4/29/2024	Principal Financial Group Inc.	2,005,905	$29.73M	0.0%	-23.9%	0.718%
4/29/2024	China Universal Asset Management Co. Ltd.	53,708	$0.80M	0.1%	+81.4%	0.019%
4/25/2024	Shaker Investments LLC OH	79,087	$1.17M	0.5%	N/A	0.028%
4/23/2024	Rice Hall James & Associates LLC	1,713,825	$25.40M	1.5%	-2.1%	0.614%
4/23/2024	Raymond James Financial Services Advisors Inc.	136,754	$2.03M	0.0%	+5.0%	0.049%
4/18/2024	Diversified Trust Co	15,511	$0.23M	0.0%	+14.8%	0.006%
4/17/2024	Grimes & Company Inc.	29,250	$0.43M	0.0%	-16.4%	0.010%
4/17/2024	Hennion & Walsh Asset Management Inc.	407,429	$6.04M	0.3%	+42.4%	0.146%
3/11/2024	Vanguard Group Inc.	22,812,820	$185.47M	0.0%	+3.0%	8.168%

Data available starting January 2016

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Range

Now: $9.74

$9.36

$9.78

50 Day Range

MA: $10.10

$7.33

$11.90

52 Week Range

Now: $9.74

$3.21

$18.33

Volume

3,422,358 shs

Average Volume

7,279,200 shs

Market Capitalization

$2.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of Iovance Biotherapeutics?: Iovance Biotherapeutics' top insider shareholders include:
Wayne P Rothbaum (Director)
Merrill A Mcpeak (Director)
Iain D Dukes (Director)
Frederick G Vogt (CEO)
Learn More about top insider investors at Iovance Biotherapeutics.
Who are the major institutional investors of Iovance Biotherapeutics?: Iovance Biotherapeutics' top institutional shareholders include:
Shaker Investments LLC OH — 0.04%
Handelsbanken Fonder AB — 0.03%
Creative Planning — 0.03%
Brookstone Capital Management — 0.01%
Exchange Traded Concepts LLC — 0.01%
ORG Wealth Partners LLC — 0.00%
Learn More about top institutional investors of Iovance Biotherapeutics stock.
Which major investors are buying Iovance Biotherapeutics stock?: Within the previous quarter, IOVA stock was bought by institutional investors including:
Shaker Investments LLC OH
Handelsbanken Fonder AB
ORG Wealth Partners LLC
Brookstone Capital Management
Creative Planning
Exchange Traded Concepts LLC
In the previous year, these company insiders have bought Iovance Biotherapeutics stock:
Wayne P Rothbaum (Director)
Merrill A Mcpeak (Director)
Iain D Dukes (Director)
Frederick G Vogt (CEO)
Learn More investors buying Iovance Biotherapeutics stock.